Boards

Scientific Advisory Board
Steering Board
User Representatives

PRIMA’s Scientific Advisory Board (SAB) consists of three distinguished and high-ranked scientists from Sweden, Denmark and U.S.

The board brings extensive expertise in establishing high‑quality scientific environments and stands at the international forefront of their respective fields, closely aligned with PRIMA’s scientific priorities.

Prof. Sten Linnarsson

Photo: Ulf Sirborn

Chair of the Department of Medical Biochemistry and Biophysics, Division of Molecular Neurobiology , Karolinska Institutet, Sweden

Learn more

Prof. Ronald N. Germain

NIH Distinguished Investigator Chief, Laboratory of Immune System Biology, Chief, Lymphocyte Biology Section, Director, Center for Advanced Tissue Imaging (CAT-I), National Institute of Allergy and Infectious Diseases National Institutes of Health, USA

Learn more

Prof. Sine Hadrup

Head of Sections for Experimental & Translational Immunology, Department of Health Technology, at the Technical University of Denmark

Learn more

PRIMA’s Steering Board is composed of senior leaders representing both the host and partner institutions.

PRIMA is fortunate to be supported by a highly competent and effective steering board. Its members hold leading roles within their institutions and bring strong scientific expertise in immunology and medical research, as well as valuable experience from other Norwegian Centres of Excellence.

Prof. Dag Kvale

Head of Institute of Clinical Medicine, University of Oslo

Prof. Shuo-Wang Qiao

Photo: Øystein Horgmo, UiO

Deputy Head of Institute of Clinical Medicine, University of Oslo

Prof. Kjetil Taskén

Head of Institute for Cancer Research, Oslo University Hospital

Prof. John-Torgils Vaage

Head of Department of Immunology, Oslo University Hospital

The User Representative Board

strengthens the quality and relevance of PRIMA’s research by contributing valuable insights and lived experiences. Their engagement helps build trust and fosters strong collaboration between the Centre and the wider community.

PRIMA’s current User Representatives have solid backgrounds in patient organizations. In partnership with PRIMA, these organizations hosted an open public seminar at Radiumhospitalet in 2025 to share ongoing research activities at the Centre.

"Research provides future hope for those of us who have extensive experiences with cancer. Precision medicine also offers hope for more direct and gentle treatment. PRIMA can represent a quantum leap into such a future, which we, as users with our experience, can help shape".
Tove Nakken

Tove Nakken

Deputy head of the Lymph Cancer Association in Norway

Christine Schjerven

Lawyer, The Norwegian Cancer Society

Olav Ljøsne

Head of the Board of the Norwegian Blood Cancer Society

Previous page
Back to top
Next page